Composition for the prevention or treatment of atopic dermatitis containing an AKT signaling pathway inhibitor as an active ingredient

Atopic dermatitis treatment and candidate screening technology based on AKT signaling pathway inhibitors

This technology provides compositions for the prevention and treatment of atopic dermatitis, as well as cosmetic compositions, containing an AKT signaling pathway inhibitor—specifically a compound with a halogen and a C1–C3 alkyl group—or its salt as an active ingredient. It also provides a screening method for identifying skin-specific T-cell inhibitors by measuring changes in AKT protein activity or expression levels.

Existing atopic dermatitis treatments rely on steroid-based anti-inflammatory drugs, which can lead to drug resistance and various side effects with long-term use. Furthermore, these treatments are often merely symptomatic, failing to prevent recurring flare-ups. Additionally, while the disease is localized to skin tissue, most research has focused on systemic immune regulation via the blood, with very little exploration into targeting skin-specific T-cells.

This technology inhibits the AKT signaling pathway to reduce the number and activity of skin-specific T-cells in the epidermis and dermis, and lowers total serum IgE, providing targeted immune control at the lesion site without compromising systemic immunity. It also includes a screening system using skin-derived T-cells expressing CD69 or CD103 as markers. This can be applied to topical treatments, atopic skin care products, and drug discovery, helping to shorten the timeline for identifying candidate substances.

‍

‍

Key Features:

• Composition for preventing or treating atopic dermatitis containing a compound with a halogen and a C1–C3 alkyl group, or a pharmaceutically acceptable salt thereof, as an active ingredient
• Composition for treating atopic dermatitis containing a compound where the halogen is Cl and the substituents are isopropyl and methyl as an active ingredient
• Cosmetic composition for alleviating or improving atopic dermatitis containing a cosmetically acceptable salt of the same compound as an active ingredient
• Screening method comprising contacting a candidate substance with cells expressing AKT protein and measuring the protein's activity or expression level

‍

This invention was developed with support from the Ministry of Science and ICT for the development of skin-specific atopic dermatitis therapeutics targeting the PI3K/Akt signaling pathway.

‍